胰岛素与唑来膦酸联合治疗对2型糖尿病合并骨质疏松患者骨代谢胰岛β细胞影响分析

doi:10.3969/j.issn.1006-6233.2022.11.034

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1186 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the effect of insulin and zoledronic acid (ZOL) combination therapy on bone metabolism and pancreatic islet β cells in patients with type 2 diabetes mellitus (T2DM) complicated with osteoporosis (OP).Methods: A total of 106 patients with T2DM and OP diagnosed and treated from January 2020 to August 2021 were selected as the research subjects, and divided into control group (treated with ZOL combined with acarbose tablets) and observation group (treated with ZOL combined with insulin), 53 cases in each. Alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BAP), osteoprotegerin (OPG), insulin secretion index (HOMA-β), and insulin resistance index (HOMA-IR) were compared; adverse reactions, including Nausea/vomiting, headache, dizziness, bloating/abdominal pain, and rash were observed. Results: Before treatment, there was no significant difference in ALP, BAP, OPG, HOMA-β, HOMA-IR between the two groups (P>0.05); after treatment, ALP, BAP, OPG, HOMA-β in the observation group were higher than in the control group, and HOMA-IR was lower than in the control group (P<0.05). In the observation group, there were 2 cases of nausea/vomiting, 1 case of dizziness and 1 case of rash; 3 cases of nausea/vomiting, 1 case of headache and abdominal distension/abdominal pain, and 2 cases of dizziness in the control group; there was no statistically significant difference in the comparison of adverse reactions between the two groups (P>0.05). Conclusion: Insulin combined with ZOL has a significant effect in the treatment of T2DM complicated with OP, which is beneficial to improve bone metabolism and islet β-cell function, with high safety and no serious adverse reactions.

Key words： Insulin Zoledronic acid Type 2 diabetes mellitus Patients with osteoporosis Bone metabolism Islet β-cell function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MAI Jinhui
	MAI Yanxing
	WU Xiuqin

Cite this article:

MAI Jinhui,MAI Yanxing,WU Xiuqin. Analysis of the Effects of Insulin and Zoledronic Acid Combination Therapy on Bone Metabolism and Islet Beta Cells in Patients with T2DM Combined with OP[J]. HeBei Med, 2022, 28(11): 1926-1929.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.11.034 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I11/1926

[1] 余筱燕,叶一,汤珂珂,等.唑来膦酸联合骨化三醇治疗原发性骨质疏松症的疗效及对骨代谢、胰岛素样生长因子1和瘦素的影响[J].中国临床药学杂志,2020,29(3):161-164.
[2] 蔡志杰,董智慧,薛君.不同血糖代谢状态下老年骨质疏松患者骨钙素与脂联素及胰岛素抵抗的关系研究[J].内科急危重症杂志,2021,27(1):47-49.
[3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
[4] Genant HK,Cooper C,Poor G,et al.Interim report and recommendations of the world health organization task-force for osteoporosis[J].Osteoporos Int,1999,10(4):259-264.
[5] 李晓蕾,齐晓玲,徐礼五,等.2型糖尿病患者血清sFRP5水平与糖脂代谢、骨代谢及骨密度的关系[J].郑州大学学报(医学版),2021,56(5):666-670.
[6] 任华,张之梁,蔡伟,等.唑来膦酸联合碳酸钙D3治疗糖尿病性骨质疏松症的疗效及其对患者骨密度和骨代谢指标的影响[J].河北医学,2020,26(1):45-50.
[7] 湛文世,王龙,凌小元,等.胰岛素泵强化治疗对初诊2型糖尿病患者糖脂代谢及胰岛β细胞功能的影响[J].中南医学科学杂志,2021,49(4):427-430.
[8] 焦杨,丁石梅,张静,等.西格列汀联合格列齐特缓释片对2型糖尿病患者血糖、血脂及胰岛β细胞功能的影响[J].中华生物医学工程杂志,2020,26(6):541-545.
[9] 李硕良,冯秀娟,何华平,等.采用胰岛素泵治疗对初诊糖尿病患者胰岛β细胞功能的影响[J].中国基层医药,2021,28(4):487-490.
[10] 张晶.身痛逐瘀汤联合右归丸治疗老年糖尿病合并骨质疏松症92例[J].西部中医药,2019,32(2):92-95.
[11] Fan S,Wang Z,Li Q,et al.The relationship between BSP mRNA expression and 25(OH)D/OPG in peripheral blood of newly diagnosed T2DM patients with different bone mass[J].Endokrynol Pol,2020,71(2):160-167.